for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase ...

However, they also respond more quickly to treatment, according to Cleveland Clinic. The most common type is diffuse large ...

Full House; actor Dave Coulier said he was diagnosed with stage 3 non-Hodgkin lymphoma in October and he has began ...

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the ...

Dave Coulier has been diagnosed with Stage 3 Non-Hodgkin lymphoma, after noticing a golf ball-sized swelling in his groin.

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

Two oral presentations on the ELM-1 and pivotal ELM-2 trials will feature new analyses in settings with significant unmet needs: one in patients with diffuse large B-cell lymphoma who progressed after ...

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase ...

Brem, MD, an assistant clinical professor in the Division of Hematology/Oncology, School of Medicine at the University of ...

Scottish Medicines Consortium Accepts Kite CAR T-Cell Therapy for Earlier Use to Treat Aggressive Blood Cancers - First SMC acceptance of any CAR T-cell therapy for lymphoma patients in the ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

The drug is used for adults diagnosed with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Regulators in Scotland, the Scottish Medicines Consortium, gave it the green ...